EDIT
Price
$10.06
Change
-$1.01 (-9.12%)
Updated
Feb 29, 6:59 PM EST
61 days until earnings call
NTLA
Price
$32.12
Change
-$0.68 (-2.07%)
Updated
Feb 29, 6:59 PM EST
62 days until earnings call
Ad is loading...

Analysis and predictions EDIT vs NTLA

Header iconEDIT vs NTLA Comparison
Open Charts EDIT vs NTLABanner chart's image
Editas Medicine
Price$10.06
Change-$1.01 (-9.12%)
Volume$2.42M
CapitalizationN/A
Intellia Therapeutics
Price$32.12
Change-$0.68 (-2.07%)
Volume$2.61M
CapitalizationN/A
View a ticker or compare two or three
EDIT vs NTLA Comparison Chart

Loading...

EDITDaily Signal changed days agoGain/Loss if shorted
 
Show more...
NTLADaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
EDIT vs. NTLA commentary
Mar 01, 2024

Editas Medicine (EDIT) and Intellia Therapeutics (NTLA) are genome research companies in Cambridge, MA founded just after the advent of CRISPR technology in 2012. They develop innovative treatments with gene editing, with a high concentration of Ph.D. and M.D. employees working in multiple collaborations with large pharmaceutical companies that provide additional capital and resources. Fiercely in competition with one another, they seek niches to call their own. NTLA has focused slightly more on blood-related disorders while EDIT has primarily taken aim at cancer and neurological disorders. Both have only reported negative earnings while they strive to bring viable treatments to market. Genome research has been a contentious topic for some time, so political climate is a big variable, and news events cause wild swings in the prices of both. NTLA’s market cap grew significantly in 2021, but it remains to be seen if this will give it a lasting advantage over EDIT.

COMPARISON
Comparison
Mar 01, 2024
Stock price -- (EDIT: $10.06 vs. NTLA: $32.12)
Brand notoriety: EDIT and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDIT: 228% vs. NTLA: 253%
Market capitalization -- EDIT: $821.64M vs. NTLA: $3.09B
EDIT [@Biotechnology] is valued at $821.64M. NTLA’s [@Biotechnology] market capitalization is $3.09B. The market cap for tickers in the [@Biotechnology] industry ranges from $541.24B to $0. The average market capitalization across the [@Biotechnology] industry is $2.59B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDIT’s FA Score shows that 0 FA rating(s) are green whileNTLA’s FA Score has 0 green FA rating(s).

  • EDIT’s FA Score: 0 green, 5 red.
  • NTLA’s FA Score: 0 green, 5 red.
According to our system of comparison, EDIT is a better buy in the long-term than NTLA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDIT’s TA Score shows that 4 TA indicator(s) are bullish while NTLA’s TA Score has 5 bullish TA indicator(s).

  • EDIT’s TA Score: 4 bullish, 6 bearish.
  • NTLA’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than EDIT.

Price Growth

EDIT (@Biotechnology) experienced а +26.86% price change this week, while NTLA (@Biotechnology) price change was +18.18% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.64%. For the same industry, the average monthly price growth was +16.56%, and the average quarterly price growth was +43.85%.

Reported Earning Dates

EDIT is expected to report earnings on May 01, 2024.

NTLA is expected to report earnings on May 02, 2024.

Industries' Descriptions

@Biotechnology (+5.64% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for EDIT with price predictions.
OPEN
A.I.dvisor published
a Summary for NTLA with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
NTLA($3.09B) has a higher market cap than EDIT($822M). NTLA YTD gains are higher at: 5.346 vs. EDIT (-0.691). EDIT has higher annual earnings (EBITDA): -202.49M vs. NTLA (-506.32M). NTLA has more cash in the bank: 912M vs. EDIT (350M). EDIT has less debt than NTLA: EDIT (34.6M) vs NTLA (115M). NTLA has higher revenues than EDIT: NTLA (36.3M) vs EDIT (24.6M).
EDITNTLAEDIT / NTLA
Capitalization822M3.09B27%
EBITDA-202.49M-506.32M40%
Gain YTD-0.6915.346-13%
P/E RatioN/AN/A-
Revenue24.6M36.3M68%
Total Cash350M912M38%
Total Debt34.6M115M30%
FUNDAMENTALS RATINGS
EDIT vs NTLA: Fundamental Ratings
EDIT
NTLA
OUTLOOK RATING
1..100
195
VALUATION
overvalued / fair valued / undervalued
1..100
34
Fair valued
52
Fair valued
PROFIT vs RISK RATING
1..100
10081
SMR RATING
1..100
9796
PRICE GROWTH RATING
1..100
4146
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (34) in the Biotechnology industry is in the same range as NTLA (52). This means that EDIT’s stock grew similarly to NTLA’s over the last 12 months.

NTLA's Profit vs Risk Rating (81) in the Biotechnology industry is in the same range as EDIT (100). This means that NTLA’s stock grew similarly to EDIT’s over the last 12 months.

NTLA's SMR Rating (96) in the Biotechnology industry is in the same range as EDIT (97). This means that NTLA’s stock grew similarly to EDIT’s over the last 12 months.

EDIT's Price Growth Rating (41) in the Biotechnology industry is in the same range as NTLA (46). This means that EDIT’s stock grew similarly to NTLA’s over the last 12 months.

EDIT's P/E Growth Rating (100) in the Biotechnology industry is in the same range as NTLA (100). This means that EDIT’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EDITNTLA
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
81%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
85%
Momentum
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
83%
MACD
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
79%
Advances
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
77%
Declines
ODDS (%)
Bearish Trend 8 days ago
86%
Bearish Trend 10 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
82%
Aroon
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
EDITDaily Signal changed days agoGain/Loss if shorted
 
Show more...
NTLADaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
UMPSX47.480.76
+1.63%
ProFunds UltraMid Cap Svc
RRCOX49.680.29
+0.59%
T. Rowe Price U.S. Equity Research R
HILVX22.610.10
+0.44%
Harbor Large Cap Value Inv
LBWCX19.430.08
+0.41%
BrandywineGLOBAL Div US Large Value C
VLCGX20.520.06
+0.29%
VALIC Company I Large Capital Growth

EDIT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been closely correlated with NTLA. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if EDIT jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
-9.12%
NTLA - EDIT
69%
Closely correlated
-2.07%
BEAM - EDIT
64%
Loosely correlated
-9.45%
VCYT - EDIT
56%
Loosely correlated
-0.93%
AXON - EDIT
52%
Loosely correlated
-0.62%
FOLD - EDIT
51%
Loosely correlated
-1.08%
More

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with BEAM. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
-2.07%
BEAM - NTLA
77%
Closely correlated
-9.45%
VCYT - NTLA
71%
Closely correlated
-0.93%
EDIT - NTLA
70%
Closely correlated
-9.12%
DNLI - NTLA
63%
Loosely correlated
-2.18%
DNA - NTLA
61%
Loosely correlated
N/A
More